Wood M J, Ogan P H, McKendrick M W, Care C D, McGill J I, Webb E M
Department of Communicable and Tropical Diseases, East Birmingham Hospital, United Kingdom.
Am J Med. 1988 Aug 29;85(2A):79-83.
Oral acyclovir, 800 mg five times per day for seven days, was compared with placebo in a randomized, double-blind trial conducted at three centers in the United Kingdom. The study group consisted of 364 elderly immunocompetent patients with herpes zoster who were entered within 72 hours of the onset of rash. Acyclovir significantly reduced the times to last new lesion formation (p less than 0.01), loss of vesicles (p less than 0.01), and full crusting (p = 0.03). No significant hastening of rash healing was seen in those who started therapy later than 48 hours after the onset of rash. There was also a significant reduction pain during treatment with acyclovir (p = 0.02). Acyclovir produced no effects on the frequency or severity of post-herpetic neuralgia. No clinically important adverse effects of acyclovir were reported.
在英国三个中心进行的一项随机双盲试验中，将口服阿昔洛韦（每天5次，每次800毫克，共7天）与安慰剂进行了比较。研究组由364名患有带状疱疹的免疫功能正常的老年患者组成，这些患者在皮疹出现后72小时内入组。阿昔洛韦显著缩短了至最后一个新皮损形成的时间（p<0.01）、水疱消失的时间（p<0.01）和完全结痂的时间（p = 0.03）。在皮疹出现后48小时后开始治疗的患者中，未观察到皮疹愈合明显加速。在阿昔洛韦治疗期间疼痛也显著减轻（p = 0.02）。阿昔洛韦对带状疱疹后神经痛的频率或严重程度没有影响。未报告阿昔洛韦有任何具有临床意义的不良反应。
